TAMP

RenovoRx Announces $11.1 Million at Market Private Placement

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Health, Oncology, LAPC, Venture round, TAMP, Pancreatic cancer, Sale, Standard of care, Security (finance)

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
  • The proceeds from this financing, in addition to RenovoRx’s previously announced private placement on January 29, 2024 for gross proceeds of approximately $6.1 million, extend the Company’s cash runway into 2026.
  • The financing allows RenovoRx to advance its lead program, the pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), through the second interim readout and towards completion of the trial.
  • Investors will pay a purchase price of $1.4075 for each share and associated Series A Warrant and Series B Warrant, with such price being at the market for purposes of Nasdaq Stock Market rules.

Goalsetter Secures $9.6 Million in Series A Extension Funding to Help American Families Learn to Save, Spend, Invest and Build Wealth

Retrieved on: 
Monday, March 25, 2024
Deutsche Bank, Health, Mutual aid (organization theory), MassMutual, TAMP, Gen, Learning, TIAA, Nike, Partnership, UBS, CEE, Social media, Council for Economic Education, Envestnet, Student, Woman, Liberty Bank, Council, Economics, Generation Z, Webster Bank, Language, InTouch, Parent

BROOKLYN, N.Y., March 25, 2024 /PRNewswire/ -- Goalsetter, an award-winning spending, saving, wealth building and financial education platform designed for the whole family, announced today the closing of a $9.6 million Series A extension round. This newest round for Goalsetter was led by an affiliate of Edward Jones and MassMutual through its MM Catalyst Fund. Series A investors Fiserv, Webster Bank, Seae Ventures, Astia Fund, and Partnership Fund for New York City also participated in the round along with new investors Reseda Group and InTouchCU.

Key Points: 
  • BROOKLYN, N.Y., March 25, 2024 /PRNewswire/ -- Goalsetter, an award-winning spending, saving, wealth building and financial education platform designed for the whole family, announced today the closing of a $9.6 million Series A extension round.
  • This newest round for Goalsetter was led by an affiliate of Edward Jones and MassMutual through its MM Catalyst Fund.
  • The Series A extension funding will give Goalsetter the runway necessary to continue forging new B2B alliances while successfully implementing existing programs ahead of a Series B raise.
  • "Our new Series A extension marks a significant milestone for Goalsetter as we continue to redefine financial education and inclusion across America," said Goalsetter Founder and CEO Tanya Van Court.

UP Fintech: Client Assets Hit Record High, Over 75% from Clients in Markets such as SG; 2023 Net Income Surged by 237%

Retrieved on: 
Wednesday, March 20, 2024
Bitcoin, ESOP, PR, SGX, TAMP, Software as a service, Growth, Communication, CHESS, Tiger, ASX, News, IPO, Fintech, CME, Employee Stock Ownership Plan, Investment, AUM, Quarter, Depreciation, HK, ETF

In 2023, the company added 123,110 funded accounts, mainly from markets outside the Chinese mainland, surpassing annual guidance of 100,000.

Key Points: 
  • In 2023, the company added 123,110 funded accounts, mainly from markets outside the Chinese mainland, surpassing annual guidance of 100,000.
  • This drove a quarter-over-quarter increase of 62.1% and a year-over-year increase of 118.5% in total client assets, reaching US$30.6 billion.
  • Our global funded clients and assets have surged over tenfold, with revenue nearly quadrupling and net incomes compounding at a rate of 72%.
  • In 2023, UponeShare added 116 new corporate clients, bringing the total number of serviced corporate clients to 535.

ENVESTNET'S CONNECTED PLATFORM NAMED LEADER IN FINANCIAL PLANNING, PORTFOLIO MANAGEMENT, TAMP AND BILLING SOLUTIONS IN 2024 T3/INSIDE INFORMATION ADVISOR SOFTWARE SURVEY

Retrieved on: 
Monday, March 11, 2024
Financial plan, TAMP, Conference, Finance, Social Security, Research, Software, Social, Investment, Ecosystem, Estate, Financial adviser

BERWYN, Pa., March 11, 2024 /PRNewswire/ -- Envestnet has been recognized by the 2024 T3/Inside Information Advisor Software Survey as a leader in Financial Planning, Portfolio Management, TAMP and Billing Solutions -- reinforcing the strength, depth and breadth of its industry-leading Wealth Management Platform and commitment to supporting advisor growth and productivity through its deeply connected ecosystem. In the survey, Envestnet | MoneyGuide – Envestnet's premier financial planning software – was named the leading financial planning software provider by market share for the 17th consecutive year.

Key Points: 
  • BERWYN, Pa., March 11, 2024 /PRNewswire/ -- Envestnet has been recognized by the 2024 T3/Inside Information Advisor Software Survey as a leader in Financial Planning, Portfolio Management, TAMP and Billing Solutions -- reinforcing the strength, depth and breadth of its industry-leading Wealth Management Platform and commitment to supporting advisor growth and productivity through its deeply connected ecosystem.
  • In the survey, Envestnet | MoneyGuide – Envestnet's premier financial planning software – was named the leading financial planning software provider by market share for the 17th consecutive year.
  • Further, in the Customized Client Billing Payment category, Envestnet BillFin was also named a Software All-Star.
  • "The 2024 T3/Inside Information Software Survey, the definitive advisor buyer guide provides market share percentages and user rankings for more than 300 fintech solutions in 36 different categories.

Advyzon Investment Management (AIM) Partners with Nebo Wealth to Create Turnkey, End-to-End Solution

Retrieved on: 
Thursday, February 15, 2024
Software, Finance, Consulting, Data Management, Accounting, Professional Services, Technology, Fintech, Philosophy, Investment, RIA, ETF, Investment management, ESG, AIM, Life, TAMP, Risk, NOT, GMO, CRM, RIAS, Heart, Registered investment adviser, Partnership, Financial adviser

Advyzon Investment Management (AIM), a turnkey asset management program (TAMP) under the umbrella of comprehensive technology platform Advyzon , recently announced a partnership with Nebo Wealth , an award-winning asset allocation and portfolio design platform from global asset manager Grantham, Mayo, Van Otterloo & Co., LLC (GMO).

Key Points: 
  • Advyzon Investment Management (AIM), a turnkey asset management program (TAMP) under the umbrella of comprehensive technology platform Advyzon , recently announced a partnership with Nebo Wealth , an award-winning asset allocation and portfolio design platform from global asset manager Grantham, Mayo, Van Otterloo & Co., LLC (GMO).
  • AIM now powers and serves as a turnkey platform for Nebo Wealth, an end-to-end solution that enables Registered Investment Advisors (RIAs) to streamline and automate the process of delivering personalized portfolios for each and every client at scale.
  • “Nebo Wealth represents a leap forward in goals-based wealth management and the future of personalized portfolios,” said Martin Tarlie, Product Lead at Nebo Wealth.
  • To learn more about Advyzon Investment Management, please click here .

SMArtX Advisory Solutions Adds 13 Strategies to Its Manager Marketplace

Retrieved on: 
Thursday, February 8, 2024
Finance, Consulting, Professional Services, Asset Management, Fintech, TAMP, UMA, RIA, Growth, API

“This expansion underscores our dedication to providing clients access to diverse investment solutions, while helping asset managers reach a wider audience and accelerate their growth,” said Jonathan Pincus, CEO of SMArtX Advisory Solutions.

Key Points: 
  • “This expansion underscores our dedication to providing clients access to diverse investment solutions, while helping asset managers reach a wider audience and accelerate their growth,” said Jonathan Pincus, CEO of SMArtX Advisory Solutions.
  • “With the addition of Bahl & Gaynor and Cantor Fitzgerald, alongside expanded offerings from existing partners, SMArtX continues to evolve as the go-to platform for innovative and sophisticated managed account solutions.”
    SMArtX's continued growth is driven by two main applications of its technology: the off-the-shelf TAMP offering, which is built using SMArtX Advisory Solutions' proprietary UMA technology, and the ability to further deploy that tailored UMA technology through APIs to meet the mandates of large enterprises, RIA platforms, and hybrid broker-dealers.

GeoWealth Has Record 2023, Surpassing $28 Billion in Platform Assets

Retrieved on: 
Thursday, February 8, 2024
Software, Finance, Asset Management, Banking, Data Management, Professional Services, Technology, Fintech, TAMP, Growth, RIAS, UMA, Financial adviser

GeoWealth , a proprietary technology and turnkey asset management platform (TAMP), today announced that it has exceeded $28 billion in platform assets as of December 31, 2023, signifying a 45 percent year-over-year growth rate.

Key Points: 
  • GeoWealth , a proprietary technology and turnkey asset management platform (TAMP), today announced that it has exceeded $28 billion in platform assets as of December 31, 2023, signifying a 45 percent year-over-year growth rate.
  • The significant increase in assets is supported by an increase in accounts to more than 180,000.
  • Built specifically for RIAs, GeoWealth combines a comprehensive and fully integrated platform with best-in-class portfolio solutions.
  • GeoWealth supports a wide array of investment use cases and enables advisors to manage portfolios that are appropriately tailored to meet clients’ needs.

RenovoRx CEO Issues Letter to Shareholders

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, LAPC, Pancreatic cancer, IMU, Patient, New Drug Application, FDA, Death, TAMP, Patent Cooperation Treaty, Cancer, Patent, Letter, ASX, Gastrointestinal cancer, System, Pharmaceutical industry

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
  • 2023 was a pivotal year for RenovoRx, and we believe our accomplishments bode well for the achievement of our anticipated 2024 milestones.
  • TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating our lead product candidate, RenovoGem™ for the treatment of LAPC.
  • RenovoGem is a novel oncology drug-device combination product utilizing our TAMP administration technology combined with the FDA-approved cancer drug, gemcitabine.

NaaS Technology Secured Investment from TAMP Giant Envestnet's Mutual Fund

Retrieved on: 
Friday, February 2, 2024
Carbon, PBW, Invesco, Ali Baba, PMC, EV, TAMP, Envestnet, ETF, Fidelity, Network as a service, ELEC, CCSO, QRG, Financial adviser

BEIJING, Feb. 2, 2024 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S. listed EV charging service company in China, today announced that it has been included within the investment portfolio of PMC Diversified Equity Fund (PMDEX) in the fourth quarter of 2023.

Key Points: 
  • BEIJING, Feb. 2, 2024 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S. listed EV charging service company in China, today announced that it has been included within the investment portfolio of PMC Diversified Equity Fund (PMDEX) in the fourth quarter of 2023.
  • According to recently released SEC Form 13F data on US-based institutional investors, PMDEX, a mutual fund under the umbrella of global Turnkey Asset Management Platform (TAMP) giant Envestnet, has turned its attention to China's charging services market.
  • Envestnet (ENV.US) is one of the world's largest global TAMP platforms, and Envestnet PMC is part of the company's wealth management solutions business.
  • The fund has allocated for NaaS within its consumer retail category alongside other prominent companies such as Amazon, Pinduoduo, JD.com, and Alibaba.

RenovoRx Closes $6.1 Million Private Placement

Retrieved on: 
Monday, January 29, 2024
Biotechnology, FDA, Professional Services, Health, Pharmaceutical, Oncology, Medical Devices, Research, Science, Clinical Trials, Finance, Death, Pancreatic cancer, Patient, Cancer, TAMP, Sarcoma, Glioblastoma, DMC, Standard of care, Cougar, Data monitoring committee, Cholangiocarcinoma, Sale, Lung cancer, LAPC, Investment, Phase, Clinical trial, Gastrointestinal cancer, Pharmaceutical industry

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.
  • RenovoRx insiders, including members of the management team and Board of Directors, participated in the private placement.
  • The warrants are exercisable at a price equal to the per share price paid by the applicable investor and are exercisable for a period of five years following the closing of the private placement.
  • “I have now chosen to join as an investor in this private placement financing.